| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00198-010-1262-X |
| P698 | PubMed publication ID | 20449572 |
| P2093 | author name string | S Okuno | |
| T Yamakawa | |||
| S Shoji | |||
| S Yamada | |||
| H Nagayama | |||
| Y Nishizawa | |||
| M Inaba | |||
| Y Imanishi | |||
| E Ishimura | |||
| M Kurajoh | |||
| P2860 | cites work | Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. | Q33260606 |
| Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism | Q34552382 | ||
| The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism | Q36666922 | ||
| Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function | Q40712098 | ||
| Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes | Q42481891 | ||
| Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis | Q44835152 | ||
| Significance of Bio-intact PTH(1-84) assay in hemodialysis patients | Q45025729 | ||
| Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study | Q45249900 | ||
| Bone formation by minimodeling is more active than remodeling after parathyroidectomy | Q46277363 | ||
| Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. | Q46609121 | ||
| First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. | Q46654206 | ||
| Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism | Q46724425 | ||
| Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment | Q47760661 | ||
| Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. | Q51115984 | ||
| Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum | Q52325952 | ||
| Inter-method variability in PTH measurement: implication for the care of CKD patients. | Q53005703 | ||
| Influence of PTH assay methodology on differential diagnosis of renal bone disease. | Q53937723 | ||
| A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure | Q73194367 | ||
| Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism | Q73234395 | ||
| Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption | Q73867899 | ||
| Elecsys parathyroid hormone (PTH) not detecting the large PTH fragment hPTH (7-84)? | Q73894335 | ||
| Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure | Q74459920 | ||
| A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples | Q74468883 | ||
| Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone | Q75191463 | ||
| Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism | Q78044129 | ||
| Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism | Q79793064 | ||
| Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction | Q80551853 | ||
| Association of increased active PTH(1-84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D | Q80606749 | ||
| Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells | Q80940440 | ||
| P433 | issue | 3 | |
| P921 | main subject | hemodialysis patient | Q126109077 |
| P304 | page(s) | 923-930 | |
| P577 | publication date | 2010-05-07 | |
| P1433 | published in | Osteoporosis International | Q7107640 |
| P1476 | title | Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism | |
| P478 | volume | 22 |
| Q49573138 | Association of BAP with urinary albumin excretion in postmenopausal, but not premenopausal, non-CKD Japanese women |
| Q58557825 | Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease |
| Q44501206 | Increased active PTH(1-84) fraction as a predictor of poor mortality in male hemodialysis patients |
| Q60926159 | Parathyroid Hormone Fragments: New Targets for the Diagnosis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder |
Search more.